- Home
- MNMD vs CCSI Comparison
MNMD vs CCSI Comparison
Compare MNMD & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- CCSI
- Stock Information
- Founded
- MNMD 2019
- CCSI 2021
- Country
- MNMD United States
- CCSI United States
- Employees
- MNMD N/A
- CCSI N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- CCSI Retail: Computer Software & Peripheral Equipment
- Sector
- MNMD Health Care
- CCSI Technology
- Exchange
- MNMD Nasdaq
- CCSI Nasdaq
- Market Cap
- MNMD 509.2M
- CCSI 450.6M
- IPO Year
- MNMD N/A
- CCSI N/A
- Fundamental
- Price
- MNMD $9.22
- CCSI $26.81
- Analyst Decision
- MNMD Strong Buy
- CCSI Hold
- Analyst Count
- MNMD 7
- CCSI 5
- Target Price
- MNMD $24.71
- CCSI $27.20
- AVG Volume (30 Days)
- MNMD 1.2M
- CCSI 151.5K
- Earning Date
- MNMD 11-06-2025
- CCSI 11-06-2025
- Dividend Yield
- MNMD N/A
- CCSI N/A
- EPS Growth
- MNMD N/A
- CCSI N/A
- EPS
- MNMD N/A
- CCSI 4.15
- Revenue
- MNMD N/A
- CCSI $349,595,000.00
- Revenue This Year
- MNMD N/A
- CCSI $1.55
- Revenue Next Year
- MNMD N/A
- CCSI $1.10
- P/E Ratio
- MNMD N/A
- CCSI $6.45
- Revenue Growth
- MNMD N/A
- CCSI N/A
- 52 Week Low
- MNMD $4.70
- CCSI $17.84
- 52 Week High
- MNMD $11.02
- CCSI $32.10
- Technical
- Relative Strength Index (RSI)
- MNMD 47.40
- CCSI 65.03
- Support Level
- MNMD $8.70
- CCSI $26.05
- Resistance Level
- MNMD $9.30
- CCSI $27.15
- Average True Range (ATR)
- MNMD 0.58
- CCSI 0.73
- MACD
- MNMD -0.13
- CCSI -0.05
- Stochastic Oscillator
- MNMD 22.41
- CCSI 78.09
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About CCSI Consensus Cloud Solutions Inc.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.